Skip to main content

Kombiglyze XR FDA Approval History

FDA Approved: Yes (First approved November 5, 2010)
Brand name: Kombiglyze XR
Generic name: saxagliptin and metformin
Dosage form: Extended-Release Tablets
Company: AstraZeneca
Treatment for: Diabetes, Type 2

Kombiglyze XR (saxagliptin and metformin) is a once-daily fixed dose combination of the dipeptidyl peptidase-4 (DPP-4) inhibitor Onglyza (saxagliptin) and extended release metformin for the treatment of type 2 diabetes.

Development timeline for Kombiglyze XR

DateArticle
Nov  5, 2010Approval Kombiglyze XR (Saxagliptin and Metformin HCl Extended-Release) Tablets Approved in the U.S. for the Treatment of Type 2 Diabetes Mellitus in Adults
Mar 22, 2010U.S. Food And Drug Administration Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Onglyza (Saxagliptin) And Extended Release Metformin For The Treatment Of Type 2 Diabetes Mellitus In Adults

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.